QWhat is the mechanism of action of deucravacitinib?
Deucravacitinib is an oral medication with selective inhibition of tyrosine kinase 2 (TYK2). It binds to the inactive pseudokinase regulatory domain of TYK2 stabilizing its interaction between regulatory and catalytic domains. TYK2 mediates multiple cytokine pathways including IL-23 which in turn impacts the production of IL-17. Deucravacitinib is FDA approved for treatment in adults with moderate to severe plaque psoriasis.
- SM Hoy. Drugs, 2022.
- SOTYKTU [package insert]. Bristol-Myers Squibb Company, 2022.